Pimozide | 匹莫奇特 | R6238 | Dopamine Receptor Antagonist

首页 / / / / Pimozide

匹莫齐特 /Pimozide {[allProObj[0].p_purity_real_show]}

货号：A650543 同义名： 匹莫奇特 / R6238;NSC 170984

Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; also inhibits STAT3 and STAT5.

Pimozide 化学结构
CAS号：2062-78-4

Pimozide 3D分子结构
CAS号：2062-78-4

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Pimozide 纯度/质量文件产品仅供科研

货号：A650543 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]; • JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]; • BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]; • J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]; • PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]; 更多 >

肾上腺素能受体亚型比较
多巴胺受体亚型比较
STAT 亚型比较

产品名称	Adrenergic Receptor ↓ ↑	α-adrenergic receptor ↓ ↑	β-adrenergic receptor ↓ ↑	纯度
Ivabradine HCl	✔			98%
Maprotiline hydrochloride	✔			98%
Cisatracurium besylate	✔			98%
Yohimbine HCI		✔		99+%
BMY 7378		++ α2C-adrenoceptor, pKi: 6.54 α1D-adrenoceptor, pKi: 5.1	+ β1-adrenoceptor, pIC50: 5.1	97%
Asenapine maleate		++++ α2A-adrenergic receptor, pKi: 8.9 α2B-adrenergic receptor, pKi: 8.9		97%
Piribedil		++ adrenoceptor α2C, pKi: 7.2 adrenoceptor α2A, pKi: 7.1		98%
Prazosin HCl		✔		95%
Silodosin		✔		98%
Phenoxybenzamine HCl		✔		98%
Naftopidil		+++ α1A-adrenergic receptor, Ki: 3.7 nM α1D-adrenergic receptor, Ki: 20 nM		98%
Naftopidil 2HCl		+ α1-adrenergic receptor, IC50: 0.2 μM		97%
Alfuzosin HCl		✔		98%
Terazosin HCl		✔		99%
Atipamezole		✔		95%
Phentolamine methanesulfonate salt		✔		99%
Doxazosin mesylate		✔		98%
Tolazoline HCl		✔		98%
Zenidolol hydrochloride			++++ β1-adrenergic receptor, Ki: 611nM β2-adrenergic receptor, Ki: 0.7nM	98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	D1 receptor ↓ ↑	D2 receptor ↓ ↑	D3 receptor ↓ ↑	D4 receptor ↓ ↑	D5 receptor ↓ ↑	DAT ↓ ↑	Dopamine receptor ↓ ↑	其他靶点	纯度
Penfluridol	+ Dopamine receptor, Ki: 1.6 μM								98%
Ansofaxine HCl	++ Dopamine receptor, IC50: 491 nM								98%
Tetrahydroberberine,THB		+ D2 receptor, pKi: 6.08							98+%
Prochlorperazine Maleate		✔							95%
Olanzapine		✔							99+%
Trifluoperazine		++++ Dopamine D2 receptor, IC50: 1.1 nM							98%
Ropinirole hydrochloride		++ D2 receptor, Ki: 29 nM							99%
Lurasidone		++++ D2 receptor, Ki: 1 nM							98%
Levosulpiride		✔							99+%
Pridopidine		✔							95%
Metoclopramide		✔					✔		99+%
Molindone HCl		✔							98%
Sulpiride		✔							99+%
Perospirone		++++ D2 receptor, Ki: 1.4 nM							99%
Perospirone HCl		++++ D2 receptor, Ki: 1.4 nM							98+%
Phenothiazine		✔							98%
Pimozide	+ Dopamine D1 receptor, Ki: 6600 nM	+++ Dopamine D2 receptor, Ki: 3.0 nM	++++ Dopamine D3 receptor, Ki: 0.83 nM						98%
Rotundine	++ D1 receptor, IC50: 166 nM	+ D2 receptor, IC50: 1.47 μM	+ D3 receptor, IC50: 3.25 μM						98%
Domperidone		✔							99+%
ONC206		✔							97%
Pimethixene maleate	++ Dopamine D1 Receptor, pKi: 6.37	+++ Dopamine D2 Receptor, pKi: 8.19		++ Dopamine D4.4 Receptor, pKi: 7.54					97%
Loxapine succinate	++ D1 receptor (human), Ki: 26 nM D2 receptor (Human), Ki: 62 nM	++ D2 receptor (human), Ki: 24 nM D2 receptor (bovine), Ki: 26 nM		+++ D4 receptor (human), Ki: 7.5 nM					99%
Chlorprothixene	+++ D1 receptor, Ki: 18 nM	+++ D2 receptor, Ki: 2.96 nM	+++ D3 receptor, Ki: 4.56 nM		+++ D5 receptor, Ki: 9 nM				98%
SCH-23390 HCl	++++ D1 dopamine receptor, Ki: 0.2 nM				++++ D5 dopamine receptor, Ki: 0.3 nM				98%
MPP+ iodide						✔			97%
σ1 Receptor antagonist-1						+ DAT, pKi: 5.8			97%
Benztropine mesylate						++ DAT, IC50: 118 nM			98%
Azaperone							✔		98%
Ziprasidone HCl							✔		98+%
Paliperidone							✔		98%
Alizapride HCl							✔		99+%
Amisulpride							✔		98%
Quetiapine hemifumarate							✔	Adrenergic Receptor	98%
Clozapine N-oxide							✔		99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	STAT1 ↓ ↑	STAT3 ↓ ↑	STAT5 ↓ ↑	纯度
Nifuroxazide	✔			98%
Fludarabine	✔			98%
Artesunate		✔		98%
BP-1-102		+++ STAT3, Kd: 504 nM		99%+
Niclosamide		++ STAT3, IC50: 0.7 μM		98%
Napabucasin		✔		98%
Cryptotanshinone		++ STAT3, IC50: 4.6 μM		98%
Stattic		+ STAT3, IC50: 5.1 μM		98%
NSC 74859		+ STAT3, IC50: 86 μM		99%+
Ochromycinone		✔		98%
HO-3867		✔		97%
C188-9		++++ STAT3, Kd: 4.7 nM		99%+
HJC0152		✔		98%
SH5-07		✔		97%
SH-4-54		++++ STAT3, Kd: 300 nM	+++ STAT5, Kd: 464 nM	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Pimozide 生物活性

靶点	D3 receptor Dopamine D3 receptor, Ki:0.83 nM D1 receptor Dopamine D1 receptor, Ki:6600 nM D2 receptor Dopamine D2 receptor, Ki:3.0 nM
描述	Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; also inhibits STAT3 and STAT5.

Pimozide 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02191358	-		Completed	-	United States, California ... 展开 >> Dr. Michael Dao Garden Grove, California, United States, 92844 United States, Colorado Kaiser Permanente Colorado Denver, Colorado, United States, 80011 United States, Kentucky Gill Heart Institute Lexington, Kentucky, United States, 40508 United States, Maryland IRC Clinics Towson, Maryland, United States, 21204 United States, Massachusetts Internal Medicine & Cardiology Associates Fall River, Massachusetts, United States, 02720 Prima CARE Fall River, Massachusetts, United States, 02720 United States, Virginia Carilion Clinic Christiansburg, Virginia, United States, 24073 收起 <<
NCT02374567	Dementia Depr... 展开 >>ession Schizophrenia Psychosomatic Disorders Anxiety Disorders 收起 <<	Phase 3	Terminated	-	Germany ... 展开 >> Bezirkskrankenhaus Augsburg Augsburg, Germany Krankenhaus Hedwigshöhe Berlin, Germany Hannover Medical School Hannover, Germany, 30625 Asklepios Fachklinikum Lübben Lübben, Germany Asklepios Fachklinikum Teupitz Teupitz, Germany 收起 <<
NCT02600741	-		Completed	-	-

Pimozide 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.17mL

0.43mL

0.22mL

10.83mL

2.17mL

1.08mL

21.67mL

4.33mL

2.17mL

Pimozide 技术信息

CAS号	2062-78-4
分子式	C₂₈H₂₉F₂N₃O
分子量	461.546

别名	匹莫奇特 ;R6238;NSC 170984;Opiran.;Orap
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末

溶解度

DMSO: 16 mg/mL(34.67 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02191358	-		Completed	-	United States, California ... 展开 >> Dr. Michael Dao Garden Grove, California, United States, 92844 United States, Colorado Kaiser Permanente Colorado Denver, Colorado, United States, 80011 United States, Kentucky Gill Heart Institute Lexington, Kentucky, United States, 40508 United States, Maryland IRC Clinics Towson, Maryland, United States, 21204 United States, Massachusetts Internal Medicine & Cardiology Associates Fall River, Massachusetts, United States, 02720 Prima CARE Fall River, Massachusetts, United States, 02720 United States, Virginia Carilion Clinic Christiansburg, Virginia, United States, 24073 收起 <<
NCT02374567	Dementia Depr... 展开 >>ession Schizophrenia Psychosomatic Disorders Anxiety Disorders 收起 <<	Phase 3	Terminated	-	Germany ... 展开 >> Bezirkskrankenhaus Augsburg Augsburg, Germany Krankenhaus Hedwigshöhe Berlin, Germany Hannover Medical School Hannover, Germany, 30625 Asklepios Fachklinikum Lübben Lübben, Germany Asklepios Fachklinikum Teupitz Teupitz, Germany 收起 <<
NCT02600741	-		Completed	-	-
NCT02307396	Schizophrenia ... 展开 >> Schizophrenia and Disorders With Psychotic Features Schizoaffective Disorders 收起 <<	Phase 4	Completed	-	Germany ... 展开 >> Psychiatrische Klinik und Poliklinik fuer Psychiatrie und Psychotherapie der Technischen Universitaet Muenchen am Klinikum rechts der Isar Munich, Bavaria, Germany, 81675 收起 <<
NCT02101801	Healthy Individuals	Not Applicable	Completed	-	Israel ... 展开 >> Hadassah Medical Organization Jerusalem, Israel, 91120 收起 <<
NCT02582736	-		Completed	-	Canada, Ontario ... 展开 >> Women's College Hospital, Women's College Research Institute Toronto, Ontario, Canada, M5G 1N8 收起 <<
NCT00699894	Postoperative Nausea and Vomit... 展开 >>ing 收起 <<	Not Applicable	Withdrawn(Logistical difficult... 展开 >>ies running the study) 收起 <<	-	United States, New York ... 展开 >> Long Island Jewish Medical Center/Schneider's Children Hospital New Hyde Park, New York, United States, 11040 收起 <<
NCT00004652	Tourette Syndrome	Phase 2	Completed	-	-
NCT02435095	Schizophrenia	Phase 4	Recruiting	April 2019	Germany ... 展开 >> RWTH University Hospital Aachen Recruiting Aachen, NRW, Germany, 52074 Contact: Sabrina Schaffrath saschaffrath@ukaachen.de Contact: Sarah Lammertz slammertz@ukaachen.de Alexianer Aachen GmbH Not yet recruiting Aachen, Germany, 52062 Zentrum für Neurologie und Seelische Gesundheit im Kapuziner Karree Aachen Not yet recruiting Aachen, Germany, 52062 Contact: Frank Bergmann, Dr. med. LVR Klinik Bonn Recruiting Bonn, Germany, 53111 LVR Klinik Düren Not yet recruiting Düren, Germany, 52353 Klinik und Poliklinik für Psychiatrie und Psychotherapie der Heinrich-Heine-Universität Düsseldorf Recruiting Düsseldorf, Germany, 40629 LVR Klinik Essen Not yet recruiting Essen, Germany, 45147 ViaNobis Gangelt Recruiting Gangelt, Germany, 52538 Klinik Königshof (Abteilung für Allgemeine Psychiatrie) Recruiting Krefeld, Germany, 47807 LVR Klinik Langenfeld Recruiting Langenfeld, Germany, 40764 LVR Klinik Viersen Not yet recruiting Viersen, Germany, 41749 收起 <<
NCT00374244	-		Completed	-	-
NCT00158223	Schizophrenia ... 展开 >> Psychotic Disorders 收起 <<	Phase 4	Completed	-	United States, New York ... 展开 >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Manhattan Psychiatric Center New York, New York, United States, 10035 Pilgrim Psychiatric Center W. Brentwood, New York, United States, 11717 收起 <<
NCT00158223	-		Completed	-	-
NCT02463825	Amyotrophic Lateral Sclerosis ... 展开 >>(ALS) 收起 <<	Phase 2	Active, not recruiting	December 2021	Canada, Alberta ... 展开 >> South Health Campus Calgary, Alberta, Canada, T3M 1M4 收起 <<
NCT01765829	Psychosis Nos/Other	Phase 3	Unknown	November 2015	Spain ... 展开 >> Mental Health Unit Villamartín Recruiting Villamartín, Cádiz, Spain, 11650 Contact: José María Mongil San Juan, MD 0034956040209 cheman45@gmail.com Principal Investigator: José María Mongil San Juan, MD Mental Health Unit Baza Recruiting Baza, Granada, Spain, 18800 Contact: Eva Bravo Barba, MD eva.bravo.barba@gmail.com Principal Investigator: Eva Bravo Barba, MD Mental Health Unit Motril Recruiting Motril, Granada, Spain, 18600 Contact: María Luisa Barrigón Estévez, MD 0034958038849 marial.barrigon.sspa@juntadeandalucia.es Principal Investigator: María Luisa Barrigón Estévez, MD Mental Health Unit Andújar Recruiting Andújar, Jaén, Spain, 23740 Contact: Fernando Sarramea Crespo, MD, PhD 0034953021717 fernandosarramea@hotmail.com Principal Investigator: Farnando Sarramea Crespo, MD, PhD Mental Health Unit Martos Recruiting Martos, Jaén, Spain, 23600 Contact: Miguel Ortigosa Luque, MD migueortigosa@hotmail.com Principal Investigator: Miguel Ortigosa Luque, MD Mental Health Unit Miraflores Not yet recruiting Alcobendas, Madrid, Spain, 28100 Contact: María Luisa Zamarro Arraz, MD, PhD 0034916530108 zamarroluisa@yahoo.es Principal Investigator: María Luisa Zamarro Arraz, MD, PhD Hospital Infanta Sofía Not yet recruiting San Sebastian de los Reyes, Madrid, Spain, 28702 Contact: María Rosario Gutiérrez Labrador, MD rosagutierrez@psiquiatra.e.telefonica.net Principal Investigator: María Rosario Guitiérrez Labrador, MD Mental Health Unit Valle del Guadalhorce Not yet recruiting Cártama, Málaga, Spain, 29580 Contact: Daniel Gutiérrez Castillo, MD 0034951033931 dgutierrezcastillo@gmail.com Principal Investigator: Daniel Gutiérrez Castillo, MD Mental Health Unit Las Lagunas Not yet recruiting Fuengiróla, Málaga, Spain, 29650 Contact: María Isabel Osuna Carmona, MD maribelosunac@hotmail.com Principal Investigator: María Isabel Osuna Carmona, MD Fundación Argibide Not yet recruiting Pamplona, Navarra, Spain, 31007 Contact: Ignacio Mata Pastor, MD, PhD 0034948266650 nacho.mata70@gmail.com Principal Investigator: Ignacio Mata Pastor, MD, PhD Hospital El Tomillar Recruiting Dos Hermanas, Seville, Spain, 41700 Contact: Joaquín Carlos Martín Muñoz, MD, PhD 0034955016083 joaquinmartin@hotmail.com Principal Investigator: Joaquín Carlos Martín Muñoz, MD, PhD Hospital Francesc de Borja Recruiting Gandía, Valencia, Spain, 46700 Contact: María Lacruz Silvestre, MD, PhD maria.lacruz.silvestre@gmail.com Principal Investigator: María Lacruz Silvestre, MD, PhD Hospital de Basurto Not yet recruiting Bilbao, Spain, 48013 Contact: Sonia Bustamante Madariaga, MD, Phd 0034944 006137 sonia.bustamantemadariaga@osakidetza.net Principal Investigator: Sonia Bustamante Madariaga, MD, PhD Mental Health Unit Tetuán Not yet recruiting Madrid, Spain, 28003 Contact: Mariano Hernández Monsalve, MD, PhD 0034915347363 hergoico@gmail.com Contact: Ruth Berdún Pe, MD ruthberdun@yahoo.es Principal Investigator: Mariano Hernández Monsalve, MD, PhD Lafora Hospital Not yet recruiting Madrid, Spain, 28049 Contact: Juan Dios Molina Martín, MD, PhD jmolinamar@hotmail.com Principal Investigator: Juan Dios Molina Martín, MD, PhD Hospital Carlos Haya Recruiting Málaga, Spain, 29009 Contact: Fermín Mayoral Cleríes, Md, PhD fermin.mayoral.sspa@juntadeandalucia.es Principal Investigator: Fermín Mayoral Cleríes, MD, PhD Virgen del Rocío Hospital Recruiting Seville, Spain, 41013 Contact: Clara M. Rosso Fernández, MD 0034955013414 claram.rosso.sspa@juntadeandalucia.es Contact: Miguel Ruiz Veguilla, MD, PhD 0034955013414 mruizveguilla@yahoo.com Principal Investigator: Miguel Ruiz Veguilla, MD, PhD 收起 <<
NCT03272503	ALS Amyotroph... 展开 >>ic Lateral Sclerosis 收起 <<	Phase 2	Recruiting	December 31, 2019	Canada, Alberta ... 展开 >> Dr. Lawrence Korngut -South Health Campus Recruiting Calgary, Alberta, Canada, T3M 1M4 Contact: Janet Petrillo, MSc 403-210-7006 japetril@ucalgary.ca Dr. Wendy Johnston Recruiting Edmonton, Alberta, Canada, T6G2G3 Contact: Kelsey Tymkow 780-915-3425 tymkow@ualberta.ca Canada, New Brunswick Dr. Colleen O'Connell - Stan Cassidy Centre for Rehabilitation Recruiting Fredericton, New Brunswick, Canada, E3B 0C7 Contact: Susan McCully, MN 506-447-4095 susan.mccully@horizonnb.ca Canada, Ontario Dr. John Turnbull McMaster University/Hamilton Health Services Recruiting Hamilton, Ontario, Canada, L8N 3Z5 Contact: Daniela Trapsa 905-521-2100 ext 76365 trapsd@mcmaster.ca Dr. Christen Shoesmith Recruiting London, Ontario, Canada, N6A5A5 Contact: Christine Piechowicz, BA 519-685-8500 ext 34858 christine.piechowicz@lhsc.on.ca Dr. Lorne Zinman Sunnybrook Research Institute Recruiting Toronto, Ontario, Canada, M4N 3M5 Contact: Liane Phung, BSc 416-480-6100 ext 87561 liane.phung@sri.utoronto.ca Contact: Shirley Pham, BA 416-480-6860 shirley.pham@sunnybrook.ca Canada, Quebec Dr. Sandrine Larue - Reserche Sepmus Inc. Recruiting Greenfield Park, Quebec, Canada, J4V 2J2 Contact: Kim Desilets, B.Sc. 450-672-1931 ext 247 larue@neurorivesud.ca Dr. Genevieve Matte Recruiting Montréal, Quebec, Canada, H2L4M1 Contact: Micheline Gravel 514-890-8000 ext 13616 micheline.gravel.chum@ssss.gouv.qc.ca Contact: Stefanie Houle 514-890-8000 ext 27208 stefanie.houle.chum@ssss.gouv.qc.ca 收起 <<
NCT00374244	Schizophrenia	Phase 2	Completed	-	United States, Connecticut ... 展开 >> Connecticut Mental Health Center New Haven, Connecticut, United States, 06508 VA Connecticut Healthcare System West Haven, Connecticut, United States, 06516 收起 <<

匹莫齐特 /Pimozide {[allProObj[0].p_purity_real_show]}

Pimozide 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Pimozide 质控信息

Pimozide 生物活性

Pimozide 临床研究

Pimozide 实验方案

Pimozide 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

D3 receptor	Dopamine D3 receptor, Ki:0.83 nM
D1 receptor	Dopamine D1 receptor, Ki:6600 nM
D2 receptor	Dopamine D2 receptor, Ki:3.0 nM

匹莫齐特 /Pimozide {[allProObj[0].p_purity_real_show]}

Pimozide 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Pimozide 质控信息

Pimozide 生物活性

Pimozide 临床研究

Pimozide 实验方案

Pimozide 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Pimozide 纯度/质量文件产品仅供科研